Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02691611 · ClinicalTrials.gov registry record
Epigenetic Regulation of Immunity in Alpha-1 Anti-trypsin Deficiency
A clinical trial, sponsored by National Jewish Health.
- Completed
- Registry status
- 39
- Enrollment target
NCT02691611: Completed study, sponsored by National Jewish Health.
NCT02691611 is a clinical trial that has completed, run by National Jewish Health. The registered enrollment target is 39 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02691611 has completed, sponsored by National Jewish Health.
- COMPLETED
- Registry status
- 39 participants
- Enrollment target
Study Summary
The investigators hypothesize that environmentally influenced histone modifications regulate AM mediated inflammation, contributing to a variable clinical course of AATD, and may also influence or be influenced by the activity of AAT augmentation therapy.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2015-12 |
| Est. Completion | 2020-07 |
What the finished NCT02691611 record still lists
NCT02691611 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 39 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02691611 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02691611 about?
NCT02691611 is a clinical study titled "Epigenetic Regulation of Immunity in Alpha-1 Anti-trypsin Deficiency". The investigators hypothesize that environmentally influenced histone modifications regulate AM mediated inflammation, contributing to a variable clinical course of AATD, and may also influence or be influenced by the activity of AAT augmentation therapy.
What is the current status of trial NCT02691611?
This trial is currently completed. The enrollment target is 39 participants. The study started on 2015-12. Estimated completion is 2020-07.
Who is sponsoring clinical trial NCT02691611?
This trial is sponsored by National Jewish Health, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia